Pathology or Normal Variant: What Constitutes a Delay in Puberty?

  title={Pathology or Normal Variant: What Constitutes a Delay in Puberty?},
  author={Carine Villanueva and Jes{\'u}s Argente},
  journal={Hormone Research in Paediatrics},
  pages={213 - 221}
Puberty is a complex maturation process that begins during fetal life and persists until the acquisition of reproduction function. The fundamental event that activates puberty occurs in the hypothalamus. A complex neuron network stimulates GnRH secretion, which stimulates pituitary gonadotropin secretion and then gonadal steroid secretion. Pubertal delay is defined as the presentation of clinical signs of puberty 2-2.5 SD later than in the normal population. Three major groups of… 

Figures and Tables from this paper

An Update on Aetiopathology, Various Genetic Causes and Management of Delayed Puberty-A Minireview

A careful assessment and knowledge of the normal physiology remains the mainstay of managing patients with DP, and novel therapies having a more physiological bases like gonadotropins or kisspeptin agonists are getting investigated for the management of hypog onadotropic hypogonadism.

Delayed Puberty: Impact on Female Fertility

Puberty is the period of life that leads to adulthood through complicated and sometimes painful physiological and psychological changes and the impact of delayed puberty might have on later fertility.

Disorders of Puberty: An Approach to Diagnosis and Management.

Patients with early isolated pubertal changes, prepubertal linear growth, and no worrisome neurologic symptoms typically have a benign pattern of development and should be monitored in the appropriate clinical context, but among patients with true precocious puberty, or full activation of the hypothalamic-pituitary-gonadal axis, most girls have an idiopathic etiology, whereas it is commonly due to identifiable pathology on imaging in boys.

Management of delayed puberty in boys: tips and tricks

A range of options now exists for the management of DP, and the treating physician should be aware of new advances in the diagnosis and therapy.

Timing and regimen of puberty induction in children with hypogonadism: a survey on the practice in Arab countries

The approach to puberty induction in boys and girls among pediatric endocrinologists in Arab countries is described, useful in developing regional consensus guidelines onuberty induction in children with hypogonadism.

Efficacy of short-term induction therapy with low-dose testosterone as a diagnostic tool in the workup of delayed growth and puberty in boys

SIT with TTG appears to be more effective to induce growth spurt, better tolerated and with a more physiological effect on pubertal induction compared to IMTT in CDGP population.

Serum relaxin‐3 hormone relationship to male delayed puberty

It is concluded that serum level of relaxin‐3 hormone is an important mediator in the pathophysiological process of normal puberty being significantly decreased in males with delayed puberty.

Effect of controlled ovarian hyperstimulation on puberty and estrus in mice offspring.

These novel findings add new evidence to better understand the potential risks of COH on the reproductive function in female offspring, raising the awareness that COH could exert adverse effects onfemale offspring, rather than just obtain more oocytes for fertilization.

Use of testosterone gel compared to intramuscular formulation for puberty induction in males with constitutional delay of growth and puberty: a preliminary study

The preliminary data confirm the efficacy of short-term Testosterone gel treatment to induce puberty compared to conventional treatment and is the first study on use of TTG for pubertal activation on CDGP population.

Factors Associated with Stunting in School Children of an Urban Community in Cameroon

Improve of socioeconomic standards, food quality, prevention of chronic pathologies and delayed puberty may help to reduce stunting in such children, while mothers’ presence for nurturing and affective attention is necessary.



Disorders of pubertal development.

The differential diagnosis of delayed puberty is between constitutional delay of growth and puberty, pubertal delay secondary to chronic disease and hypog onadotrophin-independent precocious puberty.

The GPR54 gene as a regulator of puberty.

Mutations in GPR54, a G protein-coupled receptor gene, cause autosomal recessive idiopathic hypogonadotropic hypogOnadism in humans and mice, suggesting that this receptor is essential for normal gonadotropin-releasing hormone physiology and for puberty.

Variation in the timing of puberty: clinical spectrum and genetic investigation.

How new advances in genetic research may provide the tools to help unravel the mystery of the factors that regulate the hypothalamic-pituitary-gonadal axis and modulate the timing of puberty are discussed.

The GPR54 Gene as a Regulator of Puberty

Puberty is initiated when gonadotropin-releasing hormone begins to be secreted by the hypothalamus, and complementary genetic approaches in humans and mice identified genetic factors that determine the onset of puberty.

Association of the timing of puberty with a chromosome 2 locus.

The data suggest that the pericentromeric region of chromosome 2 harbors a gene predisposing to pubertal delay in multiply affected pedigrees, and may be a component of the internal clock controlling the timing of the onset of puberty.

What is the optimal therapy for young males with hypogonadotropic hypogonadism?

Treatment is likely to be life‐long, requiring regular monitoring for its optimization and avoidance of adverse responses, and ‘Reversible genetic hypogonadotropic hypogOnadism’ is a recently described entity which has implications for the long‐term management of patients with HH.

TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction

Findings implicate Neurokinin B as a critical central regulator of human gonadal function and suggest new approaches to the pharmacological control of human reproduction and sex hormone-related diseases.

Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome.

BACKGROUND Boys with prepubertal onset of hypogonadotropic hypogonadism (HH) are at a risk of poor testis growth and impaired spermatogenesis. One potential cause for this is deficient proliferation

Patterns of inheritance of constitutional delay of growth and puberty in families of adolescent girls and boys referred to specialist pediatric care.

CDGP was almost as common in male and female relatives of the CDGP subjects seen at specialist care, challenging the view of a marked overall male preponderance of CDGP.

Neuroendocrine phenotype analysis in five patients with isolated hypogonadotropic hypogonadism due to a L102P inactivating mutation of GPR54.

GPR54 inactivation does not impede neuroendocrine onset of puberty; rather, it delays and slows down pubertal maturation of the gonadotropic axis activation.